Medplus Health

Which are the latest news on Medplus Health?

Why is Medplus Health Services Ltd falling/rising?

As of 05-Sep, Medplus Health Services Ltd's stock price is rising to Rs 679.20, reflecting a 2.49% increase. This rise is driven by strong investor interest, a recent uptick in performance, and healthy long-term growth in operating profit, despite previous declines.

As of 05-Sep, Medplus Health Services Ltd's stock price is rising, currently at Rs 679.20, reflecting a change of Rs 16.5 or 2.49% increase. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 0.49% today and has been gaining for the last two days, with a total return of 1% during this period. Additionally, the stock reached an intraday high of Rs 691, which is a 4.27% increase from its previous levels.<BR><BR>Moreover, there has been a significant rise in investor participation, with delivery volume on September 3 increasing by 479.77% compared to the 5-day average. This suggests growing interest and confidence among investors in the stock. Despite the stock trading lower than its moving averages over various periods, the current price movement indicates a positive sentiment in the short term.<BR><BR>However, it is important to note that the stock has faced challenges in the past, including a year-to-date decline of 15.75% and a one-year return of -19.17%. Nonetheless, the company's operating profit has shown healthy long-term growth, increasing at an annual rate of 33.83%. This growth in operating profit, despite the stock's overall decline, may be contributing to the current positive price movement as investors look for potential recovery and value in the stock.

Who are in the management team of Medplus Health?

The management team of Medplus Health includes Gangadi Madhukar Reddy (Chairman, Managing Director, and CEO), Anish Saraf (Director), Atul Gupta (Nominee), and independent directors Murali Sivaraman, Madhavan Ganesan, and Hiroo Mirchandani, along with Manoj Kumar Srivastava (Company Secretary and Compliance Officer).

The management team of Medplus Health includes the following individuals:<BR><BR>1. **Gangadi Madhukar Reddy** - Chairman, Managing Director, and CEO<BR>2. **Anish Saraf** - Director<BR>3. **Atul Gupta** - Nominee<BR>4. **Murali Sivaraman** - Independent Director<BR>5. **Madhavan Ganesan** - Independent Director<BR>6. **Hiroo Mirchandani** - Independent Director<BR>7. **Manoj Kumar Srivastava** - Company Secretary and Compliance Officer<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

What does Medplus Health do?

MedPlus Health Services Limited is a small-cap retail company specializing in health services, incorporated in 2006 and publicly listed since 2021. As of June 2026, it reported net sales of ₹1,880 Cr and a net profit of ₹33 Cr, with a market cap of ₹8,059 Cr.

Overview: <BR>MedPlus Health Services Limited operates in the retailing industry and is categorized as a small-cap company.<BR><BR>History: <BR>The company was incorporated in 2006 as 'MedPlus Health Services Private Limited' in Hyderabad. It transitioned to a Public Limited Company on June 1, 2021, and subsequently changed its name to MedPlus Health Services Limited on June 28, 2021. The latest reported quarterly results indicate net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1,880 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 33 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 8,059 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 38.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.49 <BR>Return on Equity: 11.12% <BR>Price to Book: 4.11 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Medplus Health?

Medplus Health's peers include A B Lifestyle, Entero Healthcar, Aditya Vision, Khemani Distrib., M K Exim India, Novelix Pharma, Purple United, Magson Retail, and Silgo Retail. Medplus has below average management risk and a 1-year return of -20.19%, better than A B Lifestyle's -35.71% but lower than Novelix Pharma's 98.36%.

Peers: The peers of Medplus Health are A B Lifestyle, Entero Healthcar, Aditya Vision, Khemani Distrib., M K Exim India, Novelix Pharma, Purple United, Magson Retail, and Silgo Retail.<BR><BR>Quality Snapshot: Excellent management risk is observed at Aditya Vision, M K Exim India, and Purple United, while Average management risk is found at A B Lifestyle, Entero Healthcar, Khemani Distrib., and the rest. Below Average management risk is noted for Medplus Health, Novelix Pharma, Magson Retail, and Silgo Retail. For Growth, Excellent growth is seen at Medplus Health, Entero Healthcar, and Purple United, while Good growth is observed at Aditya Vision, Novelix Pharma, and the rest. Below Average growth is noted for A B Lifestyle, Khemani Distrib., Magson Retail, and Silgo Retail. In terms of Capital Structure, Excellent capital structure is found at M K Exim India, Good capital structure is observed at Entero Healthcar and Khemani Distrib., while Average capital structure is noted for Aditya Vision, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Novelix Pharma at 98.36%, while the lowest is A B Lifestyle at -35.71%. Medplus Health's 1-year return is -20.19%, which is higher than A B Lifestyle's but lower than Novelix Pharma's. Additionally, Khemani Distrib., Purple United, Magson Retail, and Silgo Retail have negative six-month returns.

How big is Medplus Health?

As of 31st August, Medplus Health Services Ltd has a market capitalization of 8,059.00 Cr and reported net sales of 7,229.44 Cr and a net profit of 210.47 Cr over the latest four quarters.

As of 31st August, <BR><BR>Market Cap: Medplus Health Services Ltd has a market capitalization of 8,059.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 7,229.44 Cr, while the sum of Net Profit for the same period is 210.47 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2026. Shareholder's Funds are valued at 1,975.36 Cr, and Total Assets amount to 3,811.28 Cr.

Are Medplus Health Services Ltd latest results good or bad?

MedPlus Health Services Ltd's latest results are concerning, with a 48.14% drop in net profit quarter-on-quarter and a significant decline in operating margins, indicating operational challenges. The stock has also underperformed, down 25.95% over the past year, suggesting a negative outlook for the company.

MedPlus Health Services Ltd's latest results indicate a challenging situation for the company. In Q1 FY27, the net profit fell significantly by 48.14% quarter-on-quarter to ₹33.18 crores, marking the weakest quarterly profit performance in over two years. Year-on-year, this represents a decline of 21.67% from ₹42.36 crores in Q1 FY26.<BR><BR>While the company achieved a respectable revenue growth of 21.84% year-on-year, the operating margin has deteriorated sharply, dropping to 7.09% from 9.07% in the previous quarter. This margin compression, alongside a PAT margin that fell to 1.76%, raises concerns about the company's ability to manage costs effectively.<BR><BR>The stock has also underperformed significantly, down 25.95% over the past year, which is notably worse than the broader market and its sector peers. The combination of declining profits, shrinking margins, and poor stock performance suggests that the latest results are largely negative and reflect serious operational challenges for MedPlus. <BR><BR>Investors should be cautious, as the company needs to demonstrate substantial improvements in its operational efficiency and profitability to regain confidence.

Should I buy, sell or hold Medplus Health Services Ltd?

When is the next results date for Medplus Health Services Ltd?

The next results date for Medplus Health Services Ltd is 21 July 2026.

The next results date for Medplus Health Services Ltd is scheduled for 21 July 2026.

How has been the historical performance of Medplus Health?

Medplus Health has shown consistent growth in net sales and profitability, with net sales increasing from INR 2,870.60 crore in March 2020 to INR 6,136.05 crore in March 2025, and profit after tax rising from INR 1.79 crore to INR 150.23 crore during the same period. The company's total assets and cash flow from operating activities have also significantly improved.

Answer:<BR>The historical performance of Medplus Health shows a consistent growth trajectory in net sales and profitability over the past several years.<BR><BR>Breakdown:<BR>Medplus Health's net sales have steadily increased from INR 2,870.60 crore in March 2020 to INR 6,136.05 crore in March 2025. This growth is reflected in the total operating income, which rose from INR 2,870.60 crore to INR 6,136.05 crore during the same period. The company's total expenditure, excluding depreciation, also grew, reaching INR 5,648.95 crore in March 2025, up from INR 2,736.92 crore in March 2020. Operating profit (PBDIT) has shown a significant increase, rising from INR 150.96 crore in March 2020 to INR 535.72 crore in March 2025. The profit before tax has also improved, moving from INR 29.36 crore in March 2020 to INR 183.29 crore in March 2025, while profit after tax increased from INR 1.79 crore to INR 150.23 crore in the same timeframe. The company's total assets have grown from INR 1,308.54 crore in March 2020 to INR 3,260.27 crore in March 2025, and total liabilities have increased from INR 1,308.54 crore to INR 3,260.27 crore. Cash flow from operating activities has improved significantly, reaching INR 540 crore in March 2025, compared to INR -6 crore in March 2020. Overall, Medplus Health has demonstrated robust growth in sales, profits, and asset base over the years.

Is Medplus Health technically bullish or bearish?

As of November 24, 2025, the market trend is mildly bearish, indicated by bearish signals from the weekly MACD and KST, mixed Bollinger Bands, and no momentum from the RSI, suggesting a cautious approach as the stock remains below its 52-week high.

As of 24 November 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST both indicating bearish signals, while the daily moving averages also reflect a mildly bearish outlook. The Bollinger Bands show a mixed signal with a mildly bearish stance on the weekly and bullish on the monthly. The Dow Theory indicates no trend on the weekly and mildly bearish on the monthly, contributing to the overall bearish sentiment. The RSI shows no signals in both weekly and monthly timeframes, indicating a lack of momentum. Overall, the indicators suggest a cautious approach as the stock remains below its 52-week high.

Is Medplus Health overvalued or undervalued?

As of November 3, 2025, Medplus Health is considered attractive but overvalued due to a high PE ratio of 49.98 and low profitability metrics, despite a strong recent stock performance.

As of 3 November 2025, the valuation grade for Medplus Health has moved from very attractive to attractive. The company is currently considered overvalued based on its high PE ratio of 49.98 and an EV to EBITDA ratio of 13.80, which are significantly higher than its peers. For instance, Avenue Supermarts and Trent have PE ratios of 98.98 and 105.78, respectively, indicating that Medplus Health, while attractive, is still trading at a premium compared to its competitors.<BR><BR>In terms of key financial metrics, Medplus Health has a Price to Book Value of 0.53 and a PEG Ratio of 0.53, suggesting some growth potential relative to its price. However, the low ROCE of 1.77% and ROE of 1.06% raise concerns about profitability and efficiency. Despite a recent strong performance with a 1-year stock return of 19.68% compared to the Sensex's 5.34%, the overall valuation suggests that Medplus Health may be overvalued in the current market environment.

Who are the top shareholders of the Medplus Health?

The top shareholders of Medplus Health include promoters with 59.34% pledged holdings, led by Lone Furrow Investments Private Limited at 14.44%. Mutual funds hold 21.59%, foreign institutional investors 15.61%, and individual investors account for 13.1%.

The top shareholders of Medplus Health include a mix of promoters, mutual funds, and foreign institutional investors (FIIs). The majority shareholders are the promoters, with a significant portion of their holdings pledged at 59.34%. <BR><BR>The promoter with the highest holding is Lone Furrow Investments Private Limited, which owns 14.44% of the company. Mutual funds collectively hold 21.59% of the shares through 17 different schemes, while FIIs hold 15.61% through 147 different investors. The highest public shareholder is Nippon Life India Trustee Ltd, which holds 7.58%. Additionally, individual investors account for 13.1% of the total shareholding.

Has Medplus Health declared dividend?

No Dividend History Available